ENDPOINTS

Ideaya and Biocytogen ink $400M+ deal; Daiichi spends more on superstar ADCs

9 months ago

News Briefing

Collegium pays $525M to buy ADHD company; FDA delays Syndax decision

9 months ago

News Briefing

Galderma deprioritizes study for IL-31 drug; UCB stops work in rare encephalitis

9 months ago

News Briefing

Telix's $397M convertible bond offering; Scynexis records a $10M milestone

9 months ago

News Briefing

Grünenthal inks a deal with Valinor; Valneva gets $41M from CEPI

9 months ago

News Briefing

Rona Therapeutics raises $35M; Actuate now plans for $22M IPO

9 months ago

News Briefing

Boehringer plans to again increase R&D spending; Valneva, Pfizer to advance Lyme vaccine candidate

9 months ago

News Briefing

SK to pay up to $571M in new radiopharma deal; Aslan lets go of all employees

9 months ago

News Briefing

SOTIO, Biocytogen to jointly develop antibodies; Pliant's mid-stage liver disease data

9 months ago

News Briefing

Evofem inks women’s health deal; AusperBio brings in $37M

9 months ago

News Briefing

Faron details clinical plans for MDS drug; Cara to seek 'strategic' options

10 months ago

News Briefing

Ideaya aims to raise $263M; Immuneel extends Series A with $12M

10 months ago

News Briefing

Kymera's stock rises after derma investigation expands; Ligand buys Apeiron

10 months ago

News Briefing

Vanqua raises $45M; Aerovate to look for strategic alternatives

10 months ago

News Briefing

Innovent reworks deal with IASO; Granza raises $7M

10 months ago

News Briefing

'Optimizing R&D structure is also on the horizon, without exception,' new Sumitomo Pharma CEO says

10 months ago

Pharma

Nikkei Biotechnology

Yuhan, Ubix ink licensing deal; Xenpozyme's royalty deal

10 months ago

News Briefing

Tracon to seek ‘strategic’ options; Ovid to lay off 17 workers

10 months ago

News Briefing

Savara’s $100M offering; New biotech to test Eisai drug in Ph2

10 months ago

News Briefing

Recursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience

10 months ago

News Briefing

Taysha’s $75M offering; Augustine raises €17M

10 months ago

News Briefing

Zealand Pharma aims to raise $900M; Boehringer discontinues three Phase 2 trials

10 months ago

News Briefing

Biopharma leaders charting a path for the industry's LGBTQ+ community

10 months ago

People

Special

Corrected: Entrada raises $100M for Duchenne development; eFFECTOR winds down

10 months ago

News Briefing

about the author

author articles

Ideaya and Biocytogen ink $400M+ deal; Daiichi spends more on superstar ADCs

Collegium pays $525M to buy ADHD company; FDA delays Syndax decision

Galderma deprioritizes study for IL-31 drug; UCB stops work in rare encephalitis

Telix's $397M convertible bond offering; Scynexis records a $10M milestone

Grünenthal inks a deal with Valinor; Valneva gets $41M from CEPI

Rona Therapeutics raises $35M; Actuate now plans for $22M IPO

Boehringer plans to again increase R&D spending; Valneva, Pfizer to advance Lyme vaccine candidate

SK to pay up to $571M in new radiopharma deal; Aslan lets go of all employees

SOTIO, Biocytogen to jointly develop antibodies; Pliant's mid-stage liver disease data

Evofem inks women’s health deal; AusperBio brings in $37M

Faron details clinical plans for MDS drug; Cara to seek 'strategic' options

Ideaya aims to raise $263M; Immuneel extends Series A with $12M

Kymera's stock rises after derma investigation expands; Ligand buys Apeiron

Vanqua raises $45M; Aerovate to look for strategic alternatives

Innovent reworks deal with IASO; Granza raises $7M

'Optimizing R&D structure is also on the horizon, without exception,' new Sumitomo Pharma CEO says

Yuhan, Ubix ink licensing deal; Xenpozyme's royalty deal

Tracon to seek ‘strategic’ options; Ovid to lay off 17 workers

Savara’s $100M offering; New biotech to test Eisai drug in Ph2

Recursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience

Taysha’s $75M offering; Augustine raises €17M

Zealand Pharma aims to raise $900M; Boehringer discontinues three Phase 2 trials

Biopharma leaders charting a path for the industry's LGBTQ+ community

Corrected: Entrada raises $100M for Duchenne development; eFFECTOR winds down